Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2260 participants.
Also called NCT05410925
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,260 participants
- Registry
-
NCT05410925
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT05410925. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-08 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
- Acronym
- OPTIMA-6
- Condition
- ST Elevation Myocardial Infarction
- Intervention (Drug)
- Recombinant staphylokinase
- Intervention (Drug)
- Placebo
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
Record details
- Record id
cardio:ct-nct05410925- Content hash
258d6491c170df5d4c6981b086c1b7cd334be91a7d0c0d754d1f9a66e473a180